COOL-PolarityTE Announces Closing of Public Offering of Comm
Apr 16, 2018 14:37:51 GMT
icemandios likes this
Post by c2crusher on Apr 16, 2018 14:37:51 GMT
PolarityTE Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option
globenewswire.com/news-release/2018/04/16/1472145/0/en/PolarityTE-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriter-s-Option.html
SALT LAKE CITY, April 16, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today closed its previously announced public offering of 2,031,250 shares of its common stock, plus an additional 304,687 shares sold upon full exercise of the underwriter’s option to purchase additional shares at the public offering price less underwriting discounts and commissions. Net proceeds to the Company from the offering are expected to be approximately $34.2 million after deducting underwriting discounts and commissions and estimated offering expenses.
Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. Allele Capital Partners acted as a financial advisor to PolarityTE in connection with the offering.
PolarityTE intends to use the net proceeds from the offering for research and development of its products and product candidates, efforts toward commercialization and required registration or approval of its products and product candidates with applicable regulatory authorities and general corporate purposes.
PolarityTE’s Chief Executive Officer, Dr. Denver Lough, commented “The Company is pleased to close this offering led by several healthcare and life science focused institutions as we continue to broaden our shareholder base. This capital will further accelerate the commercial roll-out of SkinTE and development of our OsteTE programs”.
The securities described above were offered by PolarityTE pursuant to a registration statement (File No. 333-219202) which has been filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022 or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Crusher
globenewswire.com/news-release/2018/04/16/1472145/0/en/PolarityTE-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriter-s-Option.html
SALT LAKE CITY, April 16, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today closed its previously announced public offering of 2,031,250 shares of its common stock, plus an additional 304,687 shares sold upon full exercise of the underwriter’s option to purchase additional shares at the public offering price less underwriting discounts and commissions. Net proceeds to the Company from the offering are expected to be approximately $34.2 million after deducting underwriting discounts and commissions and estimated offering expenses.
Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. Allele Capital Partners acted as a financial advisor to PolarityTE in connection with the offering.
PolarityTE intends to use the net proceeds from the offering for research and development of its products and product candidates, efforts toward commercialization and required registration or approval of its products and product candidates with applicable regulatory authorities and general corporate purposes.
PolarityTE’s Chief Executive Officer, Dr. Denver Lough, commented “The Company is pleased to close this offering led by several healthcare and life science focused institutions as we continue to broaden our shareholder base. This capital will further accelerate the commercial roll-out of SkinTE and development of our OsteTE programs”.
The securities described above were offered by PolarityTE pursuant to a registration statement (File No. 333-219202) which has been filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022 or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Crusher